首頁
Rho, Inc.

11月 2025Rho, Inc.的市場佔有率分析

our integrated team of global experts ensure consistent trials that run smarter and more efficiently from development through submissions and publishing.

健康 > 生物技術和製藥

域名rhoworld.com

成立年份1984

僱員501 - 1000

年度營收$75M - $100M

Rho, Inc.

Rho, Inc.（包含公司地區）

rhoworld.com

查看更多網站流量與參與度資訊

Rho, Inc.截至 11月 2025 的總收入為 75M - 100M

Rho, Inc. 熱門網域產生的總收入

Rho, Inc. 熱門網域 3 年內的總收入

Rho, Inc. 熱門網域的總收入

rhoworld.com75M - 100M

透過銷售情報查看更多內容

Rho, Inc.的熱門網域總造訪量

了解Rho, Inc.市場觸達率與潛在市場影響力。

過去 3 個月的訪問總量

子公司細目

rhoworld.com7.2K

透過銷售情報查看更多內容

Rho, Inc.的熱門網域平均造訪時長

分析Rho, Inc.參與度指標。

過去 3 個月平均造訪時長

子公司細目

rhoworld.com00:00:39

透過銷售情報查看更多內容

Rho, Inc.的熱門網域平均頁面瀏覽量

了解Rho, Inc.如何保持使用者的參與度、培養其興趣，並鼓勵他們採取下一步。

過去 3 個月平均頁面瀏覽量

子公司細目

rhoworld.com1.60

透過銷售情報查看更多內容

Rho, Inc.按網域劃分的熱門競爭對手

11月 2025的熱門類似網站，依相似度排名

cato.com公司名Cato Research Ltd.僱員501 - 1000總部美國, 北卡羅來納, Durham年度營收$25M - $50M訪問總量--健康 > 生物技術和製藥

使用的熱門技術Rho, Inc.

这些是Rho, Inc.顶级域名使用的行业网站技术

付費廣告 (12)

DoubleClick

小工具 (7)

General Captcha

內容管理系統 (6)

WordPress

社群 (5)

Instagram

更多技術

11

檢視所有

新聞與訊號來自Rho, Inc.

透過 Similarweb 銷售訊號提醒，每當目標受眾出現新的機會或威脅時，你就會收到每日更新的已識別購買訊號。

新聞Rhoworld hired J. Marc Pipas as Senior Medical Director on Oct 19th '22.Research Triangle Park, NC – October 19, 2022 – Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, today announced the appointment of J. Marc Pipas, MD, a leading oncologist, as Senior Medical Director.

新聞Rhoworld hired Peter Schmidt as SVP, Government Partnerships, Executive Committee Member Research on Apr 19th '22.Rho Appoints Peter Schmidt, Ph.D., as SVP, Government Partnerships, Executive Committee Member Research Triangle Park, NC – April 19, 2022 – Rho, a global full-service contract research organization (CRO) with a proven track record of drug development success, has appointed Peter Schmidt, Ph.D., as Senior Vice President, Government Partnerships of Rho’s Federal Systems Division.

新聞Rhoworld launches Human Epidemiology and Response to SARS-CoV-2 study.Research Triangle Park, NC – July 26, 2021 – Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, today announced its Human Epidemiology and Response to SARS-CoV-2 (HEROS) study, to help determine the rate of the new coronavirus infection in children and their family members in the U.S. has been extended through April 2022.